Synairgen slumps by a third as AstraZeneca ditches asthma drug study

Health

Synairgen Plc said its partner AstraZeneca Plc stopped a mid-stage study for testing Synairgen’s drug candidate as a potential treatment for severe asthma, putting the brakes on the lead product in Synairgen’s pipeline.

The drug developer’s shares slumped more than a third to trade at 22.01 pence at 0722 GMT on the London Stock Exchange, becoming the biggest drag on the FTSE AIM Healthcare Index, according to Reuters.

Synairgen had licensed the drug to AstraZeneca in 2014 in a deal worth $232 million. (reut.rs/2e0slma)

The company’s pipeline has two more drugs, one being developed with AstraZeneca to treat chronic obstructive pulmonary disease, and the other being developed to treat a rare lung condition called idiopathic pulmonary fibrosis.

Synairgen said that fewer-than-expected patients had their asthma worsen in the study, making it difficult for AstraZeneca to gauge the drug’s efficiency.

AstraZeneca plans to evaluate the data collected from the study with a focus on secondary goals, which could better predict when patients’ asthma would worsen.

Synairgen said that full results from the study are expected in the first quarter of 2017.

 

H.Z

 

You might also like
Health

Al-Ghubash: Terrorist war and unilateral measures have had repercussions on health…

Health

Al-Ghabbash meets WHO Regional Director and Jordanian Health Minister in Geneva

Health

Minister of Health discusses with his counterparts in Geneva means of bilateral…

Health

More than 15,000 new cases of coronavirus in America

.. _copyright: Copyright ========= .. code-block:: none Copyright (C) 1998-2000 Tobias Ratschiller Copyright (C) 2001-2018 Marc Delisle Olivier Müller Robin Johnson Alexander M. Turek Michal Čihař Garvin Hicking Michael Keck Sebastian Mendel [check credits for more details] This program is free software; you can redistribute it and/or modify it under the terms of the GNU General Public License version 2, as published by the Free Software Foundation. This program is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the GNU General Public License for more details. You should have received a copy of the GNU General Public License along with this program. If not, see . Third party licenses ++++++++++++++++++++ phpMyAdmin includes several third-party libraries which come under their respective licenses. jQuery's license, which is where we got the files under js/vendor/jquery/ is (MIT|GPL), a copy of each license is available in this repository (GPL is available as LICENSE, MIT as js/vendor/jquery/MIT-LICENSE.txt). The download kit additionally includes several composer libraries. See their licensing information in the vendor/ directory.